Matthew Barcus
Stock Analyst at Chardan Capital
(0)
# 3306
Out of 5,231 analysts
35
Total ratings
22.73%
Success rate
3.85%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Zura Bio | Maintains: Buy | 14 12 | 1.74 | 589.66% | 2 | Nov 8, 2024 | |
uniQure | Maintains: Buy | 45 27 | 15.29 | 76.59% | 4 | Jun 22, 2023 | |
Xilio Therapeutics | Reiterates: Buy | 7 | 0.72 | 872.22% | 3 | May 30, 2023 | |
Immunovant | Maintains: Strong Buy | 21 32 | 21.75 | 47.13% | 4 | May 23, 2023 | |
Purple Biotech | Reiterates: Buy | 220 | 3.33 | 6506.61% | 3 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 144 126 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 9 | 2.98 | 202.01% | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 9 8 | 9.36 | -14.53% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 60 | 1.56 | 3746.15% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 21, 2022 |